Evidence map›Paper›PMID 32425743›Full record

ReviewFrontiers in neuroscience2020

Nanotheranostic Applications for Detection and Targeting Neurodegenerative Diseases.

Ajay Kumar, Ravi Kumar Chaudhary, Rachita Singh, Satya P Singh, Shao-Yu Wang, Zheng-Yu Hoe, Cheng-Tang Pan, Yow-Ling Shiue, Dong-Qing Wei, Aman Chandra Kaushik and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Immunomodulation in age-related disorders and nanotechnology interventions.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023
    Review
  13. Recent progress of nanomedicine in the treatment of Alzheimer's disease.Frontiers in cell and developmental biology · 2023
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 4 countries.

Ajay KumarInstitute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan.
Ravi Kumar ChaudharyDepartment of Biotechnology, Institute of Applied Medicines & Research, Ghaziabad, India.
Rachita SinghDepartment of Electrical and Electronics Engineering, IIMT Engineering College, Uttar Pradesh Technical University, Meerut, India.
Satya P SinghSchool of Computer Science & Engineering, Nanyang Technological University, Singapore, Singapore.
Shao-Yu WangDepartment of Mechanical and Electro-Mechanical Engineering, National Sun Yat-sen University, Kaohsiung, Taiwan.
Zheng-Yu HoeDepartment of Physical Medicine and Rehabilitation, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Cheng-Tang PanDepartment of Mechanical and Electro-Mechanical Engineering, National Sun Yat-sen University, Kaohsiung, Taiwan.
Yow-Ling ShiueInstitute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan.
Dong-Qing WeiKey Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
Aman Chandra KaushikKey Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
Xiaofeng DaiWuxi School of Medicine, Jiangnan University, Wuxi, China.
National Sun Yat-sen University · TWJiangnan University · CNDr. A.P.J. Abdul Kalam Technical University · INKaohsiung Veterans General Hospital · TWNanyang Technological University · SGShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanotechnology utilizes engineered materials and devices which function with biological systems at the molecular level and could transform the management of neurodegenerative diseases (NDs) by provoking, reacting to, and intermingling with target sites to stimulate physiological responses while minimizing side effects. Blood-brain barrier (BBB) protects the brain from harmful agents, and transporting drugs across the BBB is a major challenge for diagnosis, targeting, and treatment of NDs. The BBB provides severe limitations for diagnosis and treatment of Alzheimer's disease (AD), Parkinson's disease (PD), and various other neurological diseases. Conventional drug delivery systems generally fail to cross the BBB, thus are inefficient in treatment. Although gradual development through research is ensuring the progress of nanotheranostic approaches from animal to human modeling, aspects of translational applicability and safety are a key concern. This demands a deep understanding of the interaction of body systems with nanomaterials. There are various plant-based nanobioactive compounds which are reported to have applicability in the diagnosis and treatment of these NDs. This review article provides an overview of applications of nanotheranostics in AD and PD. The review also discusses nano-enabled drug delivery systems and their current and potential applications for the treatment of various NDs.

Indexed as

Alzheimer’s diseasenanocompositenanotheranosticsneurodegenerative disordersParkinson’s disease

Identifiers

PMID32425743
PMCPMC7203731
OpenAlexW3022228243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.